Method of treating diabetes by administering an anti-NKp46 antibody

Ofer Mandelboim; Angel Porgador; Yaakov Naparstek; Chamutal Gur

Method of treating diabetes by administering an anti-NKp46 antibody

Ofer Mandelboim (Inventor)
, Angel Porgador (Inventor)
, Yaakov Naparstek (Inventor)
, Chamutal Gur (Inventor)

The Shraga Segal Department of Microbiology and Immunology

Research output: Patent

Abstract

The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.

Original language	English
Patent number	US8420092 (B2)
State	Published - 16 Apr 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

@misc{6784fecfdd60450aba709ef39c0de576,

title = "Method of treating diabetes by administering an anti-NKp46 antibody",

abstract = "The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.",

author = "Ofer Mandelboim and Angel Porgador and Yaakov Naparstek and Chamutal Gur",

note = "US Patent 8,420,092; US8420092 (B2)",

year = "2013",

month = apr,

day = "16",

language = "English",

type = "Patent",

}

TY - PAT

T1 - Method of treating diabetes by administering an anti-NKp46 antibody

AU - Mandelboim, Ofer

AU - Porgador, Angel

AU - Naparstek, Yaakov

AU - Gur, Chamutal

N1 - US Patent 8,420,092

PY - 2013/4/16

Y1 - 2013/4/16

N2 - The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.

AB - The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.

M3 - Patent

M1 - US8420092 (B2)

ER -

Method of treating diabetes by administering an anti-NKp46 antibody

Abstract

UN SDGs

Fingerprint

Cite this